Atara Biotherapeutics (ATRA) Non-Current Deffered Revenue (2020 - 2024)

Atara Biotherapeutics has reported Non-Current Deffered Revenue for 5 years, with the latest figure at $470000.0 in Q3 2024.

• For the quarter ending Q3 2024, Non-Current Deffered Revenue fell 99.36% year-over-year to $470000.0; the trailing twelve-month figure through Sep 2024 stood at $470000.0 (down 99.36% YoY), and the FY2023 full-year result was $37.6 million, down 51.22% from the prior year.
• Non-Current Deffered Revenue for Q3 2024 stood at $470000.0, down from $567000.0 in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $78.0 million in Q1 2023, with the low at $470000.0 in Q3 2024.
• Historically, Non-Current Deffered Revenue has averaged $39.9 million across 5 years, with a median of $39.9 million in 2022.
• Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue surged 100.42% — and 2024, when it sank 99.36%.
• Atara Biotherapeutics' Non-Current Deffered Revenue stood at $27.8 million in 2020, then surged by 100.42% to $55.7 million in 2021, then soared by 38.22% to $77.0 million in 2022, then sank by 51.22% to $37.6 million in 2023, then tumbled by 98.75% to $470000.0 in 2024.
• The last three Non-Current Deffered Revenue figures came in at $470000.0 (Q3 2024), $567000.0 (Q2 2024), and $719000.0 (Q1 2024), per Business Quant data.